Add BrightSurf on Google Email

Science News Archive May 2015


Page 1 of 31

Article concludes no reason for laughing gas to be withdrawn from operating theaters

The European Society of Anaesthesiology and Intensive Care concludes that there is no clinically relevant evidence to withdraw nitrous oxide from clinical practice or procedural sedation. The debate focuses on the decline of its use over the last 15 years due to new, well-tolerated anaesthetic drugs and modern machines.

SourceThe European Society of Anaesthesiology and Intensive Care (ESAIC)·JournalEuropean Journal of Anaesthesiology·DateMay 31, 2015

Practice-changing study offers new option for tough breast cancer cases

The PALOMA-3 study found that palbociclib significantly extended progression-free survival for women with hormone-receptor-positive metastatic breast cancer, reducing cancer recurrence by 25% compared to chemotherapy alone. The treatment was well-tolerated and improved quality of life, offering a new hope for women with advanced disease.

SourceThomas Jefferson University·JournalNew England Journal of Medicine·DateMay 30, 2015

Genetic biomarker may predict cancer patients' response to immunotherapy drug

Researchers identified a genetic biomarker that can predict which cancer patients will respond to immunotherapy drugs like pembrolizumab. Patients with mismatch repair gene defects showed improved responses to the treatment, offering hope for previously failed patients. Larger studies are needed to assess the potential for clinical use.

SourceJohns Hopkins Medicine·JournalNew England Journal of Medicine·DateMay 29, 2015

Study: Race influences warfarin dose

A new study reveals that clinical and genetic factors affecting warfarin dose vary by race, highlighting the need for race-specific dosing equations to improve anticoagulation control. The research team found that gene variants may have different effects on dose across racial groups, particularly among African Americans.

The Lancet Diabetes & Endocrinology: 2015 ERA-EDTA Congress media alert

A collaborative meta-analysis found that creatinine-based eGFR and albuminuria improve cardiovascular prediction, particularly for mortality and heart failure. The assessment of albumin-to-creatinine ratio (ACR) outperformed traditional risk factors, suggesting its potential broad implications for cardiovascular risk classification.

SourceThe Lancet·JournalThe Lancet Diabetes & Endocrinology·DateMay 29, 2015